Department of Error: Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China (The Lancet (2020) 395(10223) (497–506), (S0140673620301835), (10.1016/S0140-6736(20)30183-5));Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China

The Lancet

Volumn 395, Issue 10223, 2020, Pages 497-506

  Huang, Chaolin ^a   Wang, Yeming ^b,c,d   Li, Xingwang ^e   Ren, Lili ^f   Zhao, Jianping ^h   Hu, Yi ^h   Zhang, Li ^a   Fan, Guohui ^b,c   Xu, Jiuyang ⁱ   Gu, Xiaoying ^b,c   Cheng, Zhenshun ^j   Yu, Ting ^a   Xia, Jiaan ^a   Wei, Yuan ^a   Wu, Wenjuan ^a   Xie, Xuelei ^a   Yin, Wen ^h   Li, Hui ^b,c,d   Liu, Min ^b   Xiao, Yan ^f   Gao, Hong ^g   Guo, Li ^f   Xie, Jungang ^h   Wang, Guangfa ^k   Jiang, Rongmeng ^e   Gao, Zhancheng ^l   Jin, Qi ^f   Wang, Jianwei ^f   Cao, Bin ^b,c,d,m   more..

^a Jinyintan Hospital   (China)

^b CHINA JAPAN FRIENDSHIP HOSPITAL   (China)

^c PEKING UNION MEDICAL COLLEGE   (China)

^d CAPITAL MEDICAL UNIVERSITY   (China)

^e CAPITAL MEDICAL UNIVERSITY   (China)

^f INSTITUTE OF PATHOGEN BIOLOGY   (China)

^g INSTITUTE OF LABORATORY ANIMAL SCIENCE   (China)

^h HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

ⁱ Tsinghua University   (China)

^j ZHONGNAN HOSPITAL OF WUHAN UNIVERSITY   (China)

^k PEKING UNIVERSITY FIRST HOSPITAL   (China)

^l PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

^m PEKING UNIVERSITY   (China)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GRANULOCYTE COLONY STIMULATING FACTOR; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 7; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; METHYLPREDNISOLONE; MONOCYTE CHEMOTACTIC PROTEIN 1; OSELTAMIVIR; OXYGEN; TUMOR NECROSIS FACTOR; COVID-19;

ADULT; ADULT RESPIRATORY DISTRESS SYNDROME; ARTICLE; CARDIOVASCULAR DISEASE; CHINA; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL OUTCOME; COHORT ANALYSIS; COMMUNITY ACQUIRED PNEUMONIA; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; CORONAVIRUS DISEASE 2019; CORONAVIRUS INFECTION; COUGHING; DIABETES MELLITUS; DIARRHEA; DISEASE SEVERITY; DYSPNEA; ELECTRONIC MEDICAL RECORD; ENVIRONMENTAL EXPOSURE; FAMILY STUDY; FATIGUE; FEMALE; FEVER; GAMMA INTERFERON INDUCIBLE PROTEIN 10 BLOOD LEVEL; GRANULOCYTE COLONY STIMULATING FACTOR BLOOD LEVEL; HEADACHE; HEART INJURY; HEMOPTYSIS; HIGH THROUGHPUT SEQUENCING; HOSPITAL ADMISSION; HUMAN; HUMAN CELL; HYPERTENSION; HYPOXEMIA; INTENSIVE CARE UNIT; INTERLEUKIN 10 BLOOD LEVEL; INTERLEUKIN 2 BLOOD LEVEL; INTERLEUKIN 7 BLOOD LEVEL; LABORATORY TEST; LYMPHOCYTOPENIA; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA BLOOD LEVEL; MALE; MONOCYTE CHEMOTACTIC PROTEIN 1 BLOOD LEVEL; MORTALITY RATE; MYALGIA; NONHUMAN; PNEUMONIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RADIODIAGNOSIS; REAL TIME REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA VIRUS INFECTION; RNAAEMIA; SARS-RELATED CORONAVIRUS; SEA FOOD; SECONDARY INFECTION; SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2; SPUTUM; STANDARDIZATION; SYMPTOM; THORAX RADIOGRAPHY; TREATMENT RESPONSE; TUMOR NECROSIS FACTOR BLOOD LEVEL; VIRUS PNEUMONIA; WORLD HEALTH ORGANIZATION; AGE DISTRIBUTION; AGED; COMORBIDITY; COMPLICATION; HOSPITALIZATION; MIDDLE AGED; PROGNOSIS; TIME FACTOR; VIROLOGY; X-RAY COMPUTED TOMOGRAPHY; YOUNG ADULT;

ADULT; AGE DISTRIBUTION; AGED; CHINA; COMORBIDITY; CORONAVIRUS INFECTIONS; COUGH; FEMALE; FEVER; HOSPITALIZATION; HUMANS; INTENSIVE CARE UNITS; MALE; MIDDLE AGED; MYALGIA; PNEUMONIA, VIRAL; PROGNOSIS; RADIOGRAPHY, THORACIC; RESPIRATORY DISTRESS SYNDROME, ADULT; TIME FACTORS; TOMOGRAPHY, X-RAY COMPUTED; YOUNG ADULT;

EID: 85078262578     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(20)30252-X     Document Type: Erratum

References (37)

1. Richman, DD, Whitley, RJ, Hayden, FG, Clinical virology. 4th edn., 2016, ASM Press, Washington.
2. Ksiazek, TG, Erdman, D, Goldsmith, CS, et al. A novel coronavirus associated with severe acute respiratory syndrome. N Engl J Med 348 (2003), 1953–1966.
3. Kuiken, T, Fouchier, RAM, Schutten, M, et al. Newly discovered coronavirus as the primary cause of severe acute respiratory syndrome. Lancet 362 (2003), 263–270.
4. Drosten, C, Günther, S, Preiser, W, et al. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N Engl J Med 348 (2003), 1967–1976.
5. de Groot, RJ, Baker, SC, Baric, RS, et al. Middle East respiratory syndrome coronavirus (MERS-CoV): announcement of the Coronavirus Study Group. J Virol 87 (2013), 7790–7792.
6. Zaki, AM, van Boheemen, S, Bestebroer, TM, Osterhaus, ADME, Fouchier, RAM, Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med 367 (2012), 1814–1820.
7. WHO. Summary of probable SARS cases with onset of illness from 1 November 2002 to 31 July 2003. https://www.who.int/csr/sars/country/table2004_04_21/en/, Dec 31, 2003. (Accessed 19 January 2020)
8. WHO. Middle East respiratory syndrome coronavirus (MERS-CoV). http://www.who.int/emergencies/mers-cov/en/, November, 2019. (Accessed 19 January 2020)
9. WHO. Novel coronavirus – China. http://www.who.int/csr/don/12-january-2020-novel-coronavirus-china/en/, Jan 12, 2020. (Accessed 19 January 2020)
10. WHO. Novel coronavirus – Thailand (ex-China). http://www.who.int/csr/don/14-january-2020-novel-coronavirus-thailand/en/, Jan 14, 2020. (Accessed 19 January 2020)
11. WHO. Novel coronavirus – Japan (ex-China). http://www.who.int/csr/don/17-january-2020-novel-coronavirus-japan-ex-china/en/, Jan 17, 2020. (Accessed 19 January 2020)
12. WHO. Novel coronavirus – Republic of Korea (ex-China). http://www.who.int/csr/don/21-january-2020-novel-coronavirus-republic-of-korea-ex-china/en/, Jan 21, 2020. (Accessed 23 January 2020)
13. CDC. First travel-related case of 2019 novel coronavirus detected in United States. https://www.cdc.gov/media/releases/2020/p0121-novel-coronavirus-travel-case.html, Jan 21, 2020. (Accessed 23 January 2020)
14. Tan, W, Zhao, X, Ma, X, et al. A novel coronavirus genome identified in a cluster of pneumonia cases — Wuhan, China 2019−2020. http://weekly.chinacdc.cn/en/article/id/a3907201-f64f-4154-a19e-4253b453d10c. (Accessed 23 January 2020)
15. Sanz, F, Gimeno, C, Lloret, T, et al. Relationship between the presence of hypoxemia and the inflammatory response measured by C-reactive protein in bacteremic pneumococcal pneumonia. Eur Respir J, 38(suppl 55), 2011, 2492.
16. Kidney disease: improving global outcomes (KDIGO) acute kidney injury work group. KDIGO clinical practice guideline for acute kidney injury. https://kdigo.org/wp-content/uploads/2016/10/KDIGO-2012-AKI-Guideline-English.pdf, March, 2012. (Accessed 23 January 2020)
17. Garner, JS, Jarvis, WR, Emori, TG, Horan, TC, Hughes, JM, CDC definitions for nosocomial infections, 1988. Am J Infect Control 16 (1988), 128–140.
18. Gao, C, Wang, Y, Gu, X, et al. Association between cardiac injury and mortality in hospitalized patients infected with avian influenza A (H7N9) virus. Crit Care Med, 2020 published online Jan 20 DOI:10.1097/CCM.0000000000004207.
19. Perlman, S, Netland, J, Coronaviruses post-SARS: update on replication and pathogenesis. Nat Rev Microbiol 7 (2009), 439–450.
20. Lee, N, Hui, D, Wu, A, et al. A major outbreak of severe acute respiratory syndrome in Hong Kong. N Engl J Med 348 (2003), 1986–1994.
21. Assiri, A, Al-Tawfiq, JA, Al-Rabeeah, AA, et al. Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: a descriptive study. Lancet Infect Dis 13 (2013), 752–761.
22. Wong, CK, Lam, CWK, Wu, AKL, et al. Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome. Clin Exp Immunol 136 (2004), 95–103.
23. Mahallawi, WH, Khabour, OF, Zhang, Q, Makhdoum, HM, Suliman, BA, MERS-CoV infection in humans is associated with a pro-inflammatory Th1 and Th17 cytokine profile. Cytokine 104 (2018), 8–13.
24. He, L, Ding, Y, Zhang, Q, et al. Expression of elevated levels of pro-inflammatory cytokines in SARS-CoV-infected ACE2+ cells in SARS patients: relation to the acute lung injury and pathogenesis of SARS. J Pathol 210 (2006), 288–297.
25. Faure, E, Poissy, J, Goffard, A, et al. Distinct immune response in two MERS-CoV-infected patients: can we go from bench to bedside?. PLoS One, 9, 2014, e88716.
26. Falzarano, D, de Wit, E, Rasmussen, AL, et al. Treatment with interferon-α2b and ribavirin improves outcome in MERS-CoV-infected rhesus macaques. Nat Med 19 (2013), 1313–1317.
27. Stockman, LJ, Bellamy, R, Garner, P, SARS: systematic review of treatment effects. PLoS Med, 3, 2006, e343.
28. Lansbury, L, Rodrigo, C, Leonardi-Bee, J, Nguyen-Van-Tam, J, Lim, WS, Corticosteroids as adjunctive therapy in the treatment of influenza. Cochrane Database Syst Rev, 2, 2019, CD010406.
29. Arabi, YM, Mandourah, Y, Al-Hameed, F, et al. Corticosteroid therapy for critically ill patients with Middle East respiratory syndrome. Am J Respir Crit Care Med 197 (2018), 757–767.
30. WHO. Clinical management of severe acute respiratory infection when novel coronavirus (nCoV) infection is suspected. https://www.who.int/internal-publications-detail/clinical-management-of-severe-acute-respiratory-infection-when-novel-coronavirus-(ncov)-infection-is-suspected, Jan 11, 2020. (Accessed 19 January 2020)
31. Chu, CM, Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings. Thorax 59 (2004), 252–256.
32. Arabi, YM, Alothman, A, Balkhy, HH, et al. Treatment of Middle East respiratory syndrome with a combination of lopinavir-ritonavir and interferon-β1b (MIRACLE trial): study protocol for a randomized controlled trial. Trials, 19, 2018, 81.
33. Sheahan, TP, Sims, AC, Graham, RL, et al. Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. Sci Transl Med, 9, 2017, eaal3653.
34. Sheahan, TP, Sims, AC, Leist, SR, et al. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat Commun, 11, 2020, 222.
35. Cui, J, Li, F, Shi, Z-L, Origin and evolution of pathogenic coronaviruses. Nat Rev Microbiol 17 (2019), 181–192.
36. Ge, X-Y, Li, J-L, Yang, X-L, et al. Isolation and characterization of a bat SARS-like coronavirus that uses the ACE2 receptor. Nature 503 (2013), 535–538.
37. Wang, M, Hu, Z, Bats as animal reservoirs for the SARS coronavirus: hypothesis proved after 10 years of virus hunting. Virol Sin 28 (2013), 315–317.